A novel prognostic model based on endoplasmic reticulum stress-associated E3 ligases and deubiquitinating enzymes in hepatocellular carcinoma.

IF 1.7 4区 医学 Q4 ONCOLOGY
Translational cancer research Pub Date : 2025-08-31 Epub Date: 2025-08-18 DOI:10.21037/tcr-2024-2403
Caixia Zhong, Yurui Liu, Kaishun Hu, Dong Yin
{"title":"A novel prognostic model based on endoplasmic reticulum stress-associated E3 ligases and deubiquitinating enzymes in hepatocellular carcinoma.","authors":"Caixia Zhong, Yurui Liu, Kaishun Hu, Dong Yin","doi":"10.21037/tcr-2024-2403","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Hepatocellular carcinoma (HCC) is classified as one of the leading malignant neoplasms worldwide, exhibiting a rising trend in its global incidence. The imperative for the development of innovative diagnostic and prognostic biomarkers is critical for improving the therapeutic and management strategies for patients with HCC. This study was undertaken to identify endoplasmic reticulum stress-associated E3 ubiquitin ligases and deubiquitinating enzymes (ERS-E3s/DUBs) and to construct a prognostic risk model for HCC.</p><p><strong>Methods: </strong>The transcriptomic and clinical data were obtained from The Cancer Genome Atlas (TCGA) database. By analyzing the transcriptomic data treated with endoplasmic reticulum stress inducers, we identified differentially expressed E3 ubiquitin ligases (E3s) and deubiquitinating enzymes (DUBs). A prognostic risk model based on ERS-E3s/DUBs was developed using least absolute shrinkage and selection operator (LASSO) and Cox regression analyses. Utilizing the Akaike Information Criterion for computation, we ascertained the most appropriate threshold for stratifying patients into distinct categories of high-risk and low-risk cohorts. Subsequently, we predicted and analyzed the survival prognosis and Gene Ontology analyses of patients in high- and low-risk groups.</p><p><strong>Results: </strong>In this study, we systematically recognized 23 ERS-E3s/DUBs and developed a liver cancer prognostic risk model founded on nine ERS-E3s/DUBs. Furthermore, we formulated a new nomogram that combines risk characteristics and clinical pathological features, which provides good predictive performance for the clinical prognosis of HCC patients.</p><p><strong>Conclusions: </strong>We identified ERS-E3s/DUBs and constructed a prognostic risk model for HCC.</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"14 8","pages":"4539-4548"},"PeriodicalIF":1.7000,"publicationDate":"2025-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12432622/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/tcr-2024-2403","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/18 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Hepatocellular carcinoma (HCC) is classified as one of the leading malignant neoplasms worldwide, exhibiting a rising trend in its global incidence. The imperative for the development of innovative diagnostic and prognostic biomarkers is critical for improving the therapeutic and management strategies for patients with HCC. This study was undertaken to identify endoplasmic reticulum stress-associated E3 ubiquitin ligases and deubiquitinating enzymes (ERS-E3s/DUBs) and to construct a prognostic risk model for HCC.

Methods: The transcriptomic and clinical data were obtained from The Cancer Genome Atlas (TCGA) database. By analyzing the transcriptomic data treated with endoplasmic reticulum stress inducers, we identified differentially expressed E3 ubiquitin ligases (E3s) and deubiquitinating enzymes (DUBs). A prognostic risk model based on ERS-E3s/DUBs was developed using least absolute shrinkage and selection operator (LASSO) and Cox regression analyses. Utilizing the Akaike Information Criterion for computation, we ascertained the most appropriate threshold for stratifying patients into distinct categories of high-risk and low-risk cohorts. Subsequently, we predicted and analyzed the survival prognosis and Gene Ontology analyses of patients in high- and low-risk groups.

Results: In this study, we systematically recognized 23 ERS-E3s/DUBs and developed a liver cancer prognostic risk model founded on nine ERS-E3s/DUBs. Furthermore, we formulated a new nomogram that combines risk characteristics and clinical pathological features, which provides good predictive performance for the clinical prognosis of HCC patients.

Conclusions: We identified ERS-E3s/DUBs and constructed a prognostic risk model for HCC.

Abstract Image

Abstract Image

Abstract Image

基于内质网应激相关E3连接酶和去泛素化酶的肝癌预后新模型。
背景:肝细胞癌(HCC)是世界范围内主要的恶性肿瘤之一,其全球发病率呈上升趋势。开发创新的诊断和预后生物标志物对于改善HCC患者的治疗和管理策略至关重要。本研究旨在鉴定内质网应激相关的E3泛素连接酶和去泛素化酶(ERS-E3s/DUBs),并构建HCC预后风险模型。方法:从癌症基因组图谱(TCGA)数据库中获取转录组学和临床数据。通过分析内质网应激诱导剂处理的转录组学数据,我们确定了差异表达的E3泛素连接酶(E3s)和去泛素化酶(DUBs)。采用最小绝对收缩和选择算子(LASSO)和Cox回归分析,建立了基于ERS-E3s/DUBs的预后风险模型。利用赤池信息标准进行计算,我们确定了最合适的阈值,将患者分为不同的高风险和低风险队列。随后,我们预测并分析了高危组和低危组患者的生存预后和基因本体分析。结果:本研究系统识别了23个ERS-E3s/ dub,建立了基于9个ERS-E3s/ dub的肝癌预后风险模型。此外,我们制定了一种新的结合风险特征和临床病理特征的nomogram,该nomogram对HCC患者的临床预后有很好的预测作用。结论:我们确定了ERS-E3s/ dub,并构建了HCC的预后风险模型。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.10
自引率
0.00%
发文量
252
期刊介绍: Translational Cancer Research (Transl Cancer Res TCR; Print ISSN: 2218-676X; Online ISSN 2219-6803; http://tcr.amegroups.com/) is an Open Access, peer-reviewed journal, indexed in Science Citation Index Expanded (SCIE). TCR publishes laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer; results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of cancer patients. The focus of TCR is original, peer-reviewed, science-based research that successfully advances clinical medicine toward the goal of improving patients'' quality of life. The editors and an international advisory group of scientists and clinician-scientists as well as other experts will hold TCR articles to the high-quality standards. We accept Original Articles as well as Review Articles, Editorials and Brief Articles.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信